Ask AI

Optimizing Outcomes With Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Best Practices for Oncology Pharmacists

Gain expert insights into the latest evidence and guidelines on anti-CD38–based treatments for high-risk smoldering or newly diagnosed multiple myeloma to individualize patient care through certified text modules with accompanying downloadable slides, a ClinicalThought commentary, and a podcast.

Share

Program Content

Events

Activities

AntiCD38 for Smoldering and NDMM
Optimizing Outcomes With Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Best Practices for Oncology Pharmacists
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 13, 2026

Provided by

ProCE Banner

Provided by ProCE, LLC.

Supporters

Supported by educational grants from Johnson & Johnson and Sanofi Genzyme.

Johnson & Johnson

Sanofi Genzyme